Yang Shengjie, Zhang Baoying, Tan Weijuan, Qi Lu, Ma Xiao, Wang Xinghe
Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Department of Internal Medicine, Zhangqiu People's Hospital, Jinan, China.
Front Genet. 2022 Jul 12;13:942267. doi: 10.3389/fgene.2022.942267. eCollection 2022.
Hepatocellular carcinoma (HCC) is regarded as one of the most common cancers in the world with a poor prognosis. Patients with HCC often have abnormal purine and uric acid metabolism, but their relationship with prognosis is unclear. Here, we collected the data of peripheral blood uric acid and clinical data in 50 patients with HCC and analyzed the relationship with prognosis. At the same time, the transcriptome sequencing data of TCGA and GEO databases were collected to analyze the changes in purine metabolic pathway activity and construct a prognosis prediction model. Based on the prognosis prediction model related to purine metabolism, we further looked for the differences in the immune microenvironment and molecular level and provided possible drug targets. We found that the level of serum uric acid was positively correlated with the prognosis of HCC. At the same time, purine metabolism and purine biosynthesis pathway activities were significantly activated in patients with a poor prognosis of HCC. The prognosis prediction model of HCC based on purine metabolism and purine biosynthesis pathway can accurately evaluate the prognosis of patients with HCC. Meanwhile, we found that there were significant changes in tumor immune infiltration microenvironment and biological function at the molecular level in patients with over-activation of purine metabolism and purine biosynthesis pathway. In addition, we found that uric acid level was positively correlated with peripheral blood leukocytes in HCC patients. In this study, we found that the level of peripheral blood uric acid in patients with HCC is correlated with their prognosis. The prognosis of patients with HCC can be accurately predicted through the metabolic process of uric acid and purine.
肝细胞癌（HCC）被认为是世界上最常见的癌症之一，预后较差。HCC患者常伴有嘌呤和尿酸代谢异常，但其与预后的关系尚不清楚。在此，我们收集了50例HCC患者的外周血尿酸数据和临床资料，并分析其与预后的关系。同时，收集TCGA和GEO数据库的转录组测序数据，分析嘌呤代谢途径活性的变化并构建预后预测模型。基于与嘌呤代谢相关的预后预测模型，我们进一步寻找免疫微环境和分子水平的差异，并提供可能的药物靶点。我们发现血清尿酸水平与HCC的预后呈正相关。同时，HCC预后较差的患者中嘌呤代谢和嘌呤生物合成途径活性显著激活。基于嘌呤代谢和嘌呤生物合成途径的HCC预后预测模型能够准确评估HCC患者的预后。同时，我们发现嘌呤代谢和嘌呤生物合成途径过度激活的患者在肿瘤免疫浸润微环境和分子水平的生物学功能上存在显著变化。此外，我们发现HCC患者尿酸水平与外周血白细胞呈正相关。在本研究中，我们发现HCC患者外周血尿酸水平与其预后相关。通过尿酸和嘌呤的代谢过程可以准确预测HCC患者的预后。
